Press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Mar 4, 2021
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired GSL Solutions, Inc. ("GSL"), a privately-held company that develops...
-
Feb 22, 2021Aims to Pair BD Antigen Test with Scanwell Health Mobile App
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Scanwell Health, a leader in smartphone-enabled at-home medical tests, today announced a...
-
Feb 17, 2021
FRANKLIN LAKES, N.J. (Feb. 17, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the U.S. Food and Drug Administration’s...
-
Feb 12, 2021
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following upcoming virtual investor conferences: The...
-
Feb 12, 2021New single test for the BD MAX™ System also shows ability to detect U.K., South African Variants
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use...
-
Feb 8, 2021
FRANKLIN LAKES, N.J. (Feb. 8, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Dev Kurdikar, 52, to the...
-
Feb 4, 2021- First fiscal quarter revenues of $5.315 billion grew 25.8% on a reported basis. On a currency-neutral basis, revenues increased 24.3%.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $5.315 billion for the first fiscal quarter ended December 31,...
-
Feb 3, 2021In conjunction with clinical findings and the results of other laboratory testing, BD Multitest™ 6-Color TBNK Reagent with BD Trucount™ Tubes may help clinicians determine the risks of Intubation with Mechanical Ventilation and also of mortality in COVID-19 patients, aiding in patient management decisions
EYSINS, Switzerland, (Feb. 3, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the CE mark of BD Multitest™ 6-Color TBNK...
-
Feb 2, 2021- There is robust evidence that the BD vascular care solution and skin antiseptic for peripheral intravenous catheters used in the CLEAN3 randomized clinical trial can help improve patient outcomes
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that new clinical data have found robust evidence that using a vascular care solution...
-
Jan 26, 2021Polen to Succeed Vince Forlenza Effective April 28
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced Tom Polen, BD CEO and president, will assume additional responsibility as chairman of...
-
Jan 25, 2021
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.83 per common share, payable on March 31, 2021 to holders of record on March 10,...
-
Jan 25, 2021Peer-Reviewed Study Suggests BD Antigen Test Likely to Be More Selective at Detecting Patients Who Are Shedding Infectious SARS-CoV-2 Virus
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the publication of a peer-reviewed study that shows BD's antigen test may be more...
-
Jan 13, 2021The BD® AbSeq Immune Discovery Panel enables researchers to execute single cell experiments with high efficiency
FRANKLIN LAKES, N.J. (Jan. 13, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial release of the BD® AbSeq...
-
Jan 12, 2021- Preliminary first fiscal quarter 2021 revenues of $5.3 billion grew 25.6% on a reported basis. On a currency-neutral basis, revenues increased 24.2%, driven by higher base revenues in all three segments and COVID diagnostic revenues.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported, preliminary unaudited financial information for the first fiscal quarter ended Dec. 31,...
-
Jan 11, 2021Peer-reviewed clinical study published in the Journal of the Association for Vascular Access supports the use of midline catheters as an effective method for blood collection while reducing number of venipunctures
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the publication of the first-ever...
-
Dec 22, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the 39th Annual J.P. Morgan Healthcare Conference via webcast....
-
Dec 18, 2020BD earns certificate under Annex IX Chapter I & III
British Standards Institution (BSI), the national standards body for the United Kingdom and a designated European Notified Body, today announces it has certified its first group of products to the...
-
Dec 16, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received pandemic orders for needles and syringes totaling more than 1...
-
Dec 14, 2020
FRANKLIN LAKES, N.J. (Dec. 14, 2020) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today released its inaugural cybersecurity annual report,...
-
Dec 9, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced publication of the results from a 52-subject human clinical trial with the BD...
-
Dec 2, 2020Investment includes new manufacturing facility in Europe
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to invest approximately $1.2 billion over a 4-year period to expand and upgrade...
-
Nov 24, 2020
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.83 per common share, an increase of 5.1% from the previous quarter. The dividend...
-
Nov 23, 2020Reports Generated by BD Synapsys™ 3.84 Informatics Solution Simplify Mandatory Public Health Reporting
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new reporting capabilities for COVID-19 data, enabling scheduled reports to be...
-
Nov 19, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on...
-
Nov 12, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired the Medical Business assets of CUBEX LLC, which is a privately-held...